Aerovate Therapeutics Drops 1.47% Amid Impending Jade Biosciences Merger
Aerovate Therapeutics, Inc. (AVTE) shares fell 1.47% on Thursday, marking the fourth consecutive day of decline, with a total drop of 3.25% over the past four days.
The primary factor influencing the recent fluctuations in Aerovate Therapeutics, Inc. (AVTE) stock price is the impending business combination with Jade Biosciences, Inc. This merger is anticipated to be finalized on April 28, 2025. Furthermore, Aerovate Therapeutics stockholders have given their approval for the proposed merger with Jade Biosciences.